Tumor Necrosis Factor Blocker [EPC]

749209 reported adverse events

Drugs of this class: ETANERCEPT INFLIXIMAB GOLIMUMAB CERTOLIZUMAB PEGOL INFLIXIMAB-AXXQ INFLIXIMAB-DYYB

These side effects are most commonly reported by patients taking drugs of the Tumor Necrosis Factor Blocker [EPC] class:

# Side effect Count
0 DRUG INEFFECTIVE 83782
1 INJECTION SITE PAIN 56742
2 ARTHRALGIA 45923
3 RHEUMATOID ARTHRITIS 41344
4 INJECTION SITE ERYTHEMA 41226
5 PAIN 40810
6 OFF LABEL USE 32905
7 FATIGUE 29881
8 PSORIASIS 26733
9 HEADACHE 25998
See all common reactions for Tumor Necrosis Factor Blocker [EPC]

Drugs of the Tumor Necrosis Factor Blocker [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 INJECTION SITE RECALL REACTION 481 0.9796
1 HUMAN ANTICHIMERIC ANTIBODY POSITIVE 282 0.9758
2 ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE 1266 0.8934
3 RED BLOOD CELL SEDIMENTATION RATE ABNORMAL 1405 0.8418
4 RHEUMATOID FACTOR POSITIVE 1629 0.8414
5 C-REACTIVE PROTEIN ABNORMAL 2176 0.7819
6 INJECTION SITE MACULE 468 0.7312
7 PEMPHIGUS 2855 0.7023
8 SYNOVITIS 5972 0.6723
9 HAND DEFORMITY 3234 0.6391
See all enriched reactions for Tumor Necrosis Factor Blocker [EPC]